Investment Thesis
BioAdaptives is a pre-revenue pharmaceutical company in severe financial distress with collapsing revenue (-55.6% YoY), massive operating losses, and negative stockholders' equity of -$1.5M indicating technical insolvency. The company faces immediate existential risk with critically low liquidity (0.07x current ratio), negative free cash flow of -$378.2K, and insufficient cash reserves to sustain operations beyond the near term.
Strengths
- Positive gross margin of 62.6% on limited revenue indicates potential product economics
- Minimal capital expenditure of $18.0K suggests lean operational structure
- Recent insider trading activity (3 Form 4 filings) shows some stakeholder engagement
Risks
- Negative stockholders' equity of -$1.5M represents technical insolvency and balance sheet bankruptcy
- Critical liquidity crisis with current ratio of 0.07x and only $59.3K cash against $1.6M liabilities
- Severe revenue decline of 55.6% YoY with operating losses of -$794.1K indicating inability to commercialize or sustain operations
- Negative free cash flow of -$378.2K with no clear path to profitability or cash generation
- Long-term debt of $75.7K against minimal equity and shrinking cash reserves
Key Metrics to Watch
- Monthly cash burn rate and runway to insolvency
- Revenue stabilization or achievement of material revenue growth
- Balance sheet restructuring or capital infusion to restore positive equity
- Operating expense reduction or achievement of operating profitability
Financial Metrics
Revenue
7.9K
Net Income
-734.6K
EPS (Diluted)
$-0.08
Free Cash Flow
-378.2K
Total Assets
124.4K
Cash
59.3K
Profitability Ratios
Gross Margin
62.6%
Operating Margin
-10,114.1%
Net Margin
-9,356.2%
ROE
N/A
ROA
-590.7%
FCF Margin
-4,817.2%
Balance Sheet & Liquidity
Current Ratio
0.07x
Quick Ratio
0.04x
Debt/Equity
N/A
Debt/Assets
1,278.2%
Interest Coverage
-23.74x
Long-term Debt
75.7K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-20T20:56:13.563672 |
Data as of: 2025-09-30 |
Powered by Claude AI